medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2023, Número 5

<< Anterior Siguiente >>

Acta Pediatr Mex 2023; 44 (5)


Náusea y vómito inducidos por quimioterapia: un enfoque pediátrico

Ortiz MD, Flores MIL, Gallardo GIY

Idioma: Español
Referencias bibliográficas: 30
Paginas: 399-407
Archivo PDF: 220.71 Kb.


FRAGMENTO

INTRODUCCIÓN

En la actualidad, el cáncer en niños ha alcanzado tasas de supervivencia global mayores al 80% en países de ingresos altos, esto debido a las estrategias de tratamiento eficaces como la quimioterapia; sin embargo, estos agentes tienen efectos a corto, mediano y largo plazo.
La náusea y el vómito inducidos por la quimioterapia tienen una repercusión física y emocional nociva, reportada incluso hasta en el 80% de los pacientes2 en quienes afecta su calidad de vida porque altera el equilibrio hidroelectrolítico, induce desnutrición, daña el aparato gastrointestinal y disminuye o descontinúa el tratamiento.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M,Clavel J, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5—a population-based study.Lancet Oncol 2014; 15 (1): 35-47. https://doi.org/10.1016/S1470-2045(13)70548-5

  2. Navari RM. Antiemetic control: toward a new standardof care for emetogenic chemotherapy. ExpertOpin Pharmacother 2009; 10 (4): 629-44. https://doi.org/10.1517/14656560902731894

  3. Aapro M, Ruffo P, Panteri R, Costa S, Piovesana V. Oncologistperspectives on chemotherapy-induced nausea and vomiting(CINV) management and outcomes: A quantitativemarket research-based survey. Cancer Rep 2018; 1 (4):e1127. https://doi.org/10.1002/cnr2.1127

  4. Gupta K, Walton R, Kataria SP. Chemotherapy-Induced Nauseaand Vomiting: Pathogenesis, Recommendations, andNew Trends. Cancer Treat Res Commun. 2021; 26:100278.https://doi.org/10.1016/j.ctarc.2020.100278

  5. Aapro M. CINV: still troubling patients after all theseyears. Support Care Cancer. 2018; 26 (S1): 5-9. https://doi.org/10.1007/s00520-018-4131-3

  6. Balaban CD, Yates BJ. What is nausea? A historical analysisof changing views. Auton Neurosci.2017; 202: 5-17. https://doi.org/10.1016/j.autneu.2016.07.003

  7. Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. Longo DL,editor. N Engl J Med 2016; 374 (14): 1356-67. doi: 10.1056/NEJMra1515442

  8. Escobar Y, Cajaraville G, Virizuela JA, Álvarez R, MuñozA, Olariaga O, et al. Incidence of chemotherapy-inducednausea and vomiting with moderately emetogenic chemotherapy:ADVICE (Actual Data of Vomiting Incidenceby Chemotherapy Evaluation) study. Support Care Cancer2015; 23 (9): 2833-40. doi:10.1007/s00520-015-2809-3

  9. Navari RM. Treatment of Breakthrough and RefractoryChemotherapy-Induced Nausea and Vomiting. BioMed ResInt 2015; 2015: 1-6. https://doi.org/10.1155/2015/595894

  10. Molassiotis A, Lee PH, Burke TA, Dicato M, Gascon P,Roila F, et al. Anticipatory Nausea, Risk Factors, and ItsImpact on Chemotherapy-Induced Nausea and Vomiting:Results From the Pan European Emesis Registry Study. JPain Symptom Manage 2016; 51 (6): 987-93. https://doi.org/10.1016/j.jpainsymman.2015.12.317

  11. Patel P, Robinson PD, Devine KA, Positano K, Cohen M,Gibson P, et al. Prevention and treatment of anticipatorychemotherapy‐induced nausea and vomiting in pediatriccancer patients and hematopoietic stem cell recipients:Clinic https://doi.org/10.1002/pbc.28947al practice guidelineupdate. Pediatr Blood Cancer 2021; 68 (5): e28947.

  12. Paw Cho Sing E, Robinson PD, Flank J, Holdsworth M,Thackray J, Freedman J, et al. Classification of the acuteemetogenicity of chemotherapy in pediatric patients: Aclinical practice guideline. Pediatr Blood Cancer 2019; 66(5): e27646. https://doi.org/10.1002/pbc.27646

  13. Dupuis LL, Robinson PD, Boodhan S, Holdsworth M, PortwineC, Gibson P, et al. Guideline for the prevention andtreatment of anticipatory nausea and vomiting due tochemotherapy in pediatric cancer patients: AnticipatoryNausea and Vomiting. Pediatr Blood Cancer 2014; 61 (8):1506-12. https://doi.org/10.1002/pbc.25063

  14. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO Guideline Update. J ClinOncol 2020; 38 (24): 2782-97.

  15. Kang HJ, Loftus S, Taylor A, DiCristina C, Green S, Zwaan CM.Aprepitant for the prevention of chemotherapy-inducednausea and vomiting in children: a randomised, doubleblind,phase 3 trial. Lancet Oncol 2015; 16 (4): 385-94.https://doi.org/10.1016/S1470-2045(15)70061-6

  16. Bakhshi S, Batra A, Biswas B, Dhawan D, Paul R, Sreenivas V.Aprepitant as an add-on therapy in children receiving highlyemetogenic chemotherapy: a randomized, double-blind,placebo-controlled trial. Support Care Cancer 2015; 23(11): 3229-37. https://doi.org/10.1007/s00520-015-2714-9

  17. Haidar C, Jeha S. Drug interactions in childhood cáncer.Lancet Oncology 2011; 12 (1): 92-97.

  18. Doggrell SA. Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) - is there stilla role after comparison with palonosetron? Expert OpinPharmacother 2017; 18 (10): 1019-26. https://doi.org/10.1080/14656566.2017.1342809

  19. Flank J, Robinson PD, Holdsworth M, Phillips R, Portwine C,Gibson P, et al. Guideline for the Treatment of Breakthroughand the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer:Breakthrough and Refractory Nausea and Vomiting.Pediatr Blood Cancer 2016; 63 (7): 1144-51. https://doi.org/10.1002/pbc.25955

  20. Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ,Bruera E, et al. 2016 MASCC and ESMO guideline updatefor the prevention of chemotherapy- and radiotherapyinducednausea and vomiting and of nausea and vomitingin advanced cancer patients. Ann Oncol 2016; 27: v119-33.https://doi.org/10.1093/annonc/mdw270

  21. US Department of Health and Human Services, & US.Department of Health and Human Services. Commonterminology criteria for adverse events. [Internet] NationalCancer Institute, 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm

  22. Dupuis LL, Boodhan S, Holdsworth M, Robinson PD, HainR, Portwine C, et al. Guideline for the prevention of acutenausea and vomiting due to antineoplastic medication inpediatric cancer patients: Antineoplastic-Induced Nauseaand Vomiting in Children. Pediatr Blood Cancer 2013; 60(7): 1073-82. https://doi.org/10.1002/pbc.24508

  23. Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL.The Safety of Metoclopramide in Children: A SystematicReview and Meta-Analysis. Drug Saf. 2016; 39 (7): 675-87.https://doi.org/10.1007/s40264-016-0418-9

  24. Schoffelen R, Lankheet AG. Drug-drug interactions withaprepitant in antiemetic prophylaxis for chemotherapy.Neth J Med 2018; 76 (3).

  25. Chu CC, Hsing CH, Shieh JP, Chien CC, Ho CM, Wang JJ.The cellular mechanisms of the antiemetic action ofdexamethasone and related glucocorticoids against vomiting.Eur J Pharmacol 2014; 722: 48-54. https://doi.org/10.1016/j.ejphar.2013.10.008

  26. Patel P, Olteanu A, Cabral S, Santesso N, Robinson PD,Dupuis LL. Dexamethasone dosing for prevention of acutechemotherapy‐induced vomiting in pediatric patients:A systematic review. Pediatr Blood Cancer. 2020;67(12).

  27. Sheikhi MA, Ebadi A, Talaeizadeh A, Rahmani H. AlternativeMethods to Treat Nausea and Vomiting from CancerChemotherapy. Chemother Res Pract. 2015; 2015:1-6.

  28. Ma TT, Zhang T, Zhang GL, Dai CF, Zhang BR, Wang XM,et al. Prevention of chemotherapy-induced nauseaand vomiting with acupuncture: A protocol for systematicreview and meta-analysis. Medicine (Baltimore).2020;99(3):e18828.

  29. Marx W, McCarthy A, Ried K, McKavanagh D, Vitetta L,Sali A, et al. The Effect of a Standardized Ginger Extracton Chemotherapy-Induced Nausea-Related Quality of Lifein Patients Undergoing Moderately or Highly EmetogenicChemotherapy: A Double Blind, Randomized, PlaceboControlled Trial. Nutrients. 2017;9(8):867.

  30. Ryan JL, Heckler CE, Roscoe JA, Dakhil SR, KirshnerJ, Flynn PJ, et al. Ginger (Zingiber officinale) reducesacute chemotherapy-induced nausea: a URCCCCOP study of 576 patients. Support Care Cancer.2012;20(7):1479-89.




2020     |     www.medigraphic.com